Asia Pacific Migraine Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 2.38 Billion |
 Market Size (Forecast Year) |
USD 4.67 Billion |
 CAGR |
% |
| Major Markets Players |
>亚太偏头痛治疗市场，按类型（发作性偏头痛、有先兆偏头痛、慢性偏头痛及其他）、治疗（急性/中止治疗、预防性/预防性治疗、非药物疗法和设备）、给药途径（口服、肠胃外、鼻腔喷雾剂及其他）、产品类型（处方药和非处方药）、类型（品牌药和通用药）、最终用户（医院、诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房及其他）划分 - 行业趋势和预测至 2029 年
市场分析和规模
偏头痛是一种常见且使人丧失行动能力的脑部疾病。头痛占全科就诊人数的 4.4%，占所有住院人数的近 5%，占神经科门诊人数的 20% 以上。大约 20% 的人在一生中的某个时刻会受到偏头痛的影响；流行病学研究表明，西欧 4.5% 的人口每月至少有 15 天会头痛，而全球研究表明，全球约有 1% 的人口患有慢性偏头痛。
Data Bridge Market Research 分析，偏头痛治疗市场在 2021 年为 23.8 亿美元，到 2029 年将飙升至 46.7 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 8.80%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
类型（发作性、有先兆的偏头痛、慢性和其他）、治疗（急性/中止治疗、预防性/预防性治疗、非药物疗法和设备）、给药途径（口服、肠胃外、鼻腔喷雾剂和其他）、产品类型（处方药和非处方药）、类型（品牌药和通用药）、最终用户（医院、诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房和其他） |
|
覆盖国家 |
亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 其他地区 |
|
涵盖的市场参与者 |
辉瑞公司（美国）、礼来公司（美国）、安进公司（美国）、葛兰素史克公司（英国）、诺华公司（瑞士）、拜耳公司（德国）、艾尔建公司（爱尔兰）、雅培公司（美国）、Allodynic Therapeutics, LLC（美国）、AOBiome（美国）、阿斯利康公司（英国）、Aurobindo Pharma USA（美国）、博士健康公司（加拿大）、Biohaven Pharmaceuticals（美国）、勃林格殷格翰国际有限公司（德国）、康泰伦特公司（美国）、雷迪博士实验室有限公司（印度）、Impel Pharmaceuticals Inc.（美国）、H. Lundbeck A/S（丹麦）、默克公司（美国） |
|
市场机会 |
|
市场定义
偏头痛是一种危及生命的神经系统疾病，其特点是反复发作剧烈的头部疼痛，最多可持续三天。头痛可持续四小时至三天，通常是单侧头痛。通常与疼痛相关的其他症状包括恶心、呕吐、对光的敏感性增加（畏光）、对声音的敏感性增加（恐音症）、四肢或腿部刺痛或麻木、出汗和腹泻。
偏头痛治疗市场动态
驱动程序
- 偏头痛的患病率和诊断率上升
偏头痛发病率大幅上升是推动市场扩张的主要因素。除此之外，偏头痛治疗报销政策的改善和精准医疗需求的增加也使市场受益。此外，治疗偏头痛的电神经刺激装置需求的增加以及具有更高临床疗效的新型后期研发药物（如降钙素基因相关肽 (CGRP) 单克隆抗体）的上市，也推动了市场的增长。
- 目前，CM 的预防性治疗正在取得重大进展
这些重大进展应促使我们重新考虑对这种毁灭性疾病的处理方法，并使我们能够保持警惕并继续进行科学的临床研究，同时牢记，只有共同的临床和科学管理策略才能改善 CM 检测、区分表型和生物标记、揭示被忽视的临床治理领域、提供个性化医疗保健和量身定制的治疗，并优化经济资源的配置。我们有责任确保充分利用新型和不断发展的治疗选择，如 OBT-A 和抗 CGRP 单克隆抗体，作为更广泛的预防文化的一部分，以大幅减少这种致命疾病对人类、社会和经济的影响。
- 供应商更加关注新兴市场
亚太地区、拉丁美洲和加勒比地区可能会推动市场增长。由于对更好的医疗设施的需求增加以及医疗基础设施的进步，预计亚太地区未来将大幅增长。此外，由于发达市场已经有些饱和，该地区为风险资本家和投资者提供了非凡的潜力。
机会
偏头痛治疗的研发支出增加，从而催生了产品线，这将促使制造商将新药投入市场，从而提高需求，而治疗急性偏头痛的技术进步也增加了需求。目前正在进行的几个研究项目可能会让制造商在开发新的、创新的、增强的偏头痛治疗药物以及其他偏头痛治疗前景方面获得竞争优势。
限制/挑战
然而，顺势疗法等替代疗法的使用以及当前偏头痛疗法的局限性、由于社交距离规范导致的临床就诊次数和偏头痛程序治疗的减少预计将在 2022 年至 2029 年的预测期内抑制市场增长。
本偏头痛治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关偏头痛治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
COVID-19 对偏头痛治疗市场的影响
COVID-19 的神经系统指征表明病毒通过嗅沟或循环进入神经系统。许多研究将 COVID-19 死亡率与心脏和肺部疾病联系起来。偏头痛还会导致更高的血管问题发生率，使偏头痛患者面临更高的 COVID-19 检测结果不理想的风险。发烧、失眠和脱水等 COVID-19 急性症状可能导致偏头痛发作。COVID-19 头痛被描述为搏动性、压迫性或刺痛性。它们大多是双侧的，持续时间更长，对镇痛药有抵抗力，在男性中更常见。偏头痛患者对疫情的长期和间接影响尤其敏感，例如抑郁、病毒引起的疲劳和焦虑。
近期发展
- 2022年2月，据Biohaven Pharmaceutical Holding Company Ltd.和辉瑞公司称，降钙素基因相关肽 (CGRP) 受体拮抗剂 Rimegepant 获得了欧洲药品管理局 (EMA) 人用药品委员会 (CHMP) 的好评。建议以 75 毫克剂量的 Rimegepant（口服溶解片形式）获得营销授权，用于成人有或无先兆偏头痛的急性治疗，以及每月至少发作四次偏头痛的成人发作性偏头痛的预防性治疗。
- 2022 年 1 月，Elyxyb（塞来昔布口服溶液）是 BioDelivery Sciences 推出的一种新型速效液体。它是首批获得 FDA 批准的即用型口服治疗药物之一，适用于有或无先兆的急性偏头痛患者。
亚太偏 头痛治疗市场范围
偏头痛治疗市场根据类型、治疗、给药途径、产品、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 情节性
- 有先兆的偏头痛
- 慢性的
- 其他的
治疗
- 急性/中止治疗
- 预防性治疗
- 非药物治疗及设备
给药途径
- 口服
- 肠外
产品
- 处方
- 在柜台
类型
- 品牌
- 通用的
终端用户
- 医院
- 诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
偏头痛治疗市场区域分析/见解
对偏头痛治疗市场进行了分析，并按国家、类型、治疗、给药途径、产品、分销渠道和最终用户提供了市场规模洞察和趋势。
偏头痛治疗市场报告涵盖的国家包括亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太地区 (APAC) 其他地区。
中国 在亚太偏头痛治疗市场占据主导地位，因为制药业是该国的领先行业之一，投资者数量不断增长。注重有机增长、城市化进程加快和可支配收入的变化都是影响市场的主要变量。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
偏头痛治疗市场还为您提供每个国家/地区资本设备医疗支出增长、偏头痛治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对偏头痛治疗市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。
竞争格局和偏头痛治疗市场份额分析
偏头痛治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对偏头痛治疗市场的关注有关。
偏头痛治疗市场的一些主要参与者包括：
- 辉瑞公司（美国）
- 礼来公司 (美国)
- 安进公司 (美国)
- 葛兰素史克公司（英国）
- 诺华公司（瑞士）
- 拜耳公司（德国）
- 艾尔建（爱尔兰）
- 雅培（美国）
- Allodynic Therapeutics, LLC（美国）
- AOBiome（美国）
- 阿斯利康（英国）
- Aurobindo Pharma USA（美国）
- Bausch Health Companies Inc.（加拿大）
- Biohaven Pharmaceuticals（美国）
- 勃林格殷格翰国际有限公司 (德国)
- Catalent, Inc（美国）
- Dr. Reddy's Laboratories Ltd.（印度）
- Impel Pharmaceuticals Inc.（美国）
- H. Lundbeck A/S（丹麦）
- 默克公司（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC MIGRAINE TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPES OF MIGRAINE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF MIGRAINE
3.1.2 GROWING FEMALE POPULATION
3.1.3 DEVELOPMENT OF NOVEL DRUGS
3.1.4 RISING AWARENESS PROGRAMS
3.1.5 AVAILABILITY OF LARGE NUMBER OF GENERIC DRUGS
3.2 RESTRAINTS
3.2.1 RECALL OF DRUGS
3.2.2 ADVERSE EFFECTS OF DRUGS
3.3 OPPORTUNITIES
3.3.1 TECHNOLOGICAL ADVANCEMENTS FOR THE TREATMENT OF ACUTE MIGRAINE
3.3.2 INCREASING R&D INVESTMENT LEADING TO PIPELINE PRODUCTS
3.3.3 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
3.4 CHALLENGES
3.4.1 USE OF ALTERNATIVE THERAPIES SUCH AS HOMEOPATHY
3.4.2 LIMITATIONS OF CURRENT MIGRAINE THERAPIES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
7 REIMBURSEMENT SCENARIO & REGULATION STATUS
7.1 REIMBURSEMENT SCENARIO
7.2 REGULATIONS
8 PIPELINE ANALYSIS
9 IMPACT OF COVID 19 PANDEMIC ON THE MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE
10.1 OVERVIEW
10.2 EPISODIC
10.3 MIGRAINE WITH AURA
10.4 CHRONIC
10.5 OTHERS
11 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ACUTE/ABORTIVE TREATMENT
11.2.1 NONSPECIFIC THERAPIES
11.2.1.1 TRIPTANS
11.2.1.1.1 SUMATRIPTAN
11.2.1.1.2 RIZATRIPTAN
11.2.1.1.3 OTHERS
11.2.1.2 OPIATES/OPOIDS
11.2.1.2.1 VICODIN
11.2.1.2.2 OXYCONTIN
11.2.1.2.3 PERCOCET
11.2.1.2.4 OTHERS
11.2.1.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
11.2.1.3.1 ASPIRIN
11.2.1.3.2 IBUPROFEN
11.2.1.3.3 ACETAMINOPHEN
11.2.1.3.4 OTHERS
11.2.1.4 ERGOT ALKALOID
11.2.1.4.1 ERGOTAMINE
11.2.1.4.2 LASMIDITAN
11.2.1.4.3 DIHYDROERGOTAMINES
11.2.1.4.4 OTHERS
11.2.1.5 ANTI-NAUSEA
11.2.1.5.1 PROCHLORPERAZINE
11.2.1.5.2 METOCLOPRAMIDE
11.2.1.5.3 CHLORPROMAZINE
11.2.1.5.4 OTHERS
11.2.1.6 OTHERS
11.2.2 ADJUNCTIVE THERAPIES
11.2.2.1 ANTIEMETICS
11.2.2.2 SEDATIVES
11.2.2.3 OTHERS
11.2.3 OTHERS
11.2.3.1 INTRANASAL LIDOCAINE
11.2.3.2 STEROIDS
11.2.3.3 OTHERS
11.3 PREVENTIVE/PROPHYLACTIC TREATMENT
11.3.1 ANTICONVULSANTS
11.3.1.1 TOPAMAX (TOPIRAMATE)
11.3.1.2 TROKENDI (TOPIRAMATE)
11.3.1.3 DEPAKOTE (DIVALPROEX SODIUM)
11.3.1.4 QUDEXY XR (TOPIRAMATE)
11.3.1.5 OTHERS
11.3.2 CALCITONIN GENE-RELATED PEPTIDE THERAPY
11.3.2.1 ERENUMAB-AOOE
11.3.2.2 GALCANEZUMAB
11.3.2.3 FREMANEZUMAB-VFRM
11.3.2.4 OTHERS
11.3.3 SELECTIVE SEROTONIN RECEPTOR AGONISTS
11.3.3.1 SUMATRIPTAN
11.3.3.2 RIZATRIPTAN
11.3.3.3 ZOLMITRIPTAN
11.3.3.4 ELETRIPTAN
11.3.3.5 FROVATRIPTAN
11.3.3.6 NARATRIPTAN
11.3.3.7 ALMOTRIPTAN MALATE
11.3.3.8 OTHERS
11.3.4 ANTIDEPRESSANTS
11.3.4.1 AMITRIPTYLINE
11.3.4.2 NORTRIPTYLINE
11.3.4.3 OTHERS
11.3.5 NSAIDS
11.3.5.1 NAPROXEN SODIUM
11.3.5.2 NAPROXEN
11.3.5.3 KETOPROFEN
11.3.5.4 FENOPROFEN
11.3.5.5 OTHERS
11.3.6 BLOOD PRESSURE-LOWERING MEDICATIONS
11.3.6.1 BETA BLOCKERS
11.3.6.1.1 PROPRANAOLOL
11.3.6.1.2 TIMOLOL
11.3.6.1.3 OTHERS
11.3.6.2 CALCIUM-CHANNEL BLOCKERS
11.3.6.2.1 VERAPAMIL
11.3.6.2.2 NIMODIPINE
11.3.6.2.3 OTHERS
11.3.7 ANGIOTENSIN BLOCKERS: ACE-IS/ARBS
11.3.7.1 CANDESARTAN
11.3.7.2 TELMISARTAN
11.3.7.3 OTHERS
11.3.8 OTHERS
11.4 NON-PHARMACOLOGICAL THERAPIES
11.4.1 ACUPUNCTURE
11.4.2 BIOFEEDBACK TECHNIQUES
11.4.3 COGNITIVE BEHAVIOR THERAPY
11.4.4 MASSAGE
11.4.5 RELAXATION
11.4.6 OTHERS
11.5 DEVICES
11.5.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
11.5.2 OTHERS
12 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.3 PARENTERAL
12.4 NASAL SPRAYS
12.5 OTHERS
13 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER
14 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE
14.1 OVERVIEW
14.2 GENERIC
14.3 BRANDED
15 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOMECARE
15.5 OTHERS
16 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACIES
16.3 RETAIL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY GEOGRAPHY
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 INDONESIA
17.1.8 THAILAND
17.1.9 MALAYSIA
17.1.10 PHILIPPINES
17.1.11 VIETNAM
17.1.12 REST OF ASIA-PACIFIC
18 ASIA PACIFIC MIGRAINE TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS AND DATA BRIDGE MARKET RESEARCH ANALYSIS
19.1 SWOT ANALYSIS
19.1.1 STRENGTH
19.1.1.1 STRONG PRODUCT PORTFOLIO
19.1.1.2 ASIA PACIFIC COMMERCIAL PRESENCE IN EMERGING MARKETS
19.1.2 WEAKNESS
19.1.2.1 DEPENDENCY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT
19.1.2.2 LITIGATION AND GOVERNMENT INVESTIGATION
19.1.3 OPPORTUNITY
19.1.3.1 EXPANDING BUSINESS THOROUGH THEIR SUBSIDIARIES
19.1.3.2 STRATEGIC INITIATIVES
19.1.4 THREAT
19.1.4.1 COMPETITIVE ENVIRONMENT
19.2 ASIA PACIFIC MIGRAINE TREATMENT MARKET: DBMR ANALYSIS
20 COMPANY PROFILE
20.1 AMGEN INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ELI LILLY AND COMPANY
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 GLAXOSMITHKLINE PLC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 NOVARTIS AG
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 ALLERGAN
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABBOTT
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 ALLODYNIC THERAPEUTICS, LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AOBIOME
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ASTRAZENECA
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 BAUSCH HEALTH COMPANIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 BIOHAVEN PHARMACEUTICALS
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 CATALENT, INC
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 DR. REDDY’S LABORATORIES LTD.
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 IMPEL NEUROPHARMA, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 LUNDBECK
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 NEURELIS, INC.
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENTS
20.21 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.)
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENTS
20.22 PFIZER INC.
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENTS
20.23 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENTS
20.24 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)
20.24.1 COMPANY SNAPSHOT
20.24.2 REVENUE ANALYSIS
20.24.3 PRODUCT PORTFOLIO
20.24.4 RECENT DEVELOPMENTS
20.25 ZOSANO PHARMA CORPORATION
20.25.1 COMPANY SNAPSHOT
20.25.2 REVENUE ANALYSIS
20.25.3 PRODUCT PORTFOLIO
20.25.4 RECENT DEVELOPMENTS
21 CONCLUSION
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT
TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT
TABLE 3 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS
TABLE 4 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 5 ASIA PACIFIC EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 6 ASIA PACIFIC MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 7 ASIA PACIFIC CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 8 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 9 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 10 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 11 ASIA PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 12 ASIA PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)
TABLE 13 ASIA PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 14 ASIA PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 15 ASIA PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 16 ASIA PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 17 ASIA PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 18 ASIA PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 19 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)
TABLE 20 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 21 ASIA PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 22 ASIA PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 23 ASIA PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 24 ASIA PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 25 ASIA PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 26 ASIA PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 27 ASIA PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 28 ASIA PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 29 ASIA PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 30 ASIA PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 31 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 32 ASIA PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 33 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 34 ASIA PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 35 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 36 ASIA PACIFIC ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 37 ASIA PACIFIC PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 38 ASIA PACIFIC NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 39 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 40 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 41 ASIA PACIFIC PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 42 ASIA PACIFIC OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 43 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44 ASIA PACIFIC GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 45 ASIA PACIFIC BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 46 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 47 ASIA PACIFIC HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 48 ASIA PACIFIC CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 49 ASIA PACIFIC HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 50 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 51 ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 52 ASIA PACIFIC HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 53 ASIA PACIFIC RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 54 ASIA PACIFIC ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 55 ASIA PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 56 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 57 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 59 ASIA-PACIFIC ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 60 ASIA-PACIFIC NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 61 ASIA-PACIFIC TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 62 ASIA-PACIFIC OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 63 ASIA-PACIFIC NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64 ASIA-PACIFIC ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 65 ASIA-PACIFIC ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 66 ASIA-PACIFIC ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 67 ASIA-PACIFIC OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 68 ASIA-PACIFIC PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70 ASIA-PACIFIC CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 71 ASIA-PACIFIC SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 72 ASIA-PACIFIC ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 73 ASIA-PACIFIC NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 74 ASIA-PACIFIC BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 75 ASIA-PACIFIC BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76 ASIA-PACIFIC CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 77 ASIA-PACIFIC ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 78 ASIA-PACIFIC NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 79 ASIA-PACIFIC DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 80 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 81 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 82 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 83 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 84 ASIA-PACIFIC MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 85 CHINA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 86 CHINA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 87 CHINA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88 CHINA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 89 CHINA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 90 CHINA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 91 CHINA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 92 CHINA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 93 CHINA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94 CHINA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 95 CHINA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 96 CHINA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 97 CHINA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 98 CHINA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD)
TABLE 99 CHINA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 100 CHINA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 101 CHINA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 102 CHINA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 103 CHINA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 104 CHINA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 105 CHINA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 106 CHINA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 107 CHINA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 108 CHINA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 109 CHINA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 110 CHINA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 111 CHINA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 112 CHINA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 113 JAPAN MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 114 JAPAN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 115 JAPAN ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 116 JAPAN NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 117 JAPAN TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 118 JAPAN OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 119 JAPAN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 120 JAPAN ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 121 JAPAN ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 122 JAPAN ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 123 JAPAN OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 124 JAPAN PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 125 JAPAN ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 126 JAPAN CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 127 JAPAN SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 128 JAPAN ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 129 JAPAN NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 130 JAPAN BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 131 JAPAN BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 132 JAPAN CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 133 JAPAN ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 134 JAPAN NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 135 JAPAN DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 136 JAPAN MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 137 JAPAN MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 138 JAPAN MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 139 JAPAN MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 140 JAPAN MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 141 INDIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 142 INDIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 143 INDIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 144 INDIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 145 INDIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 146 INDIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 147 INDIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 148 INDIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 149 INDIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 150 INDIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 151 INDIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 152 INDIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 153 INDIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 154 INDIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 155 INDIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 156 INDIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 157 INDIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 158 INDIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 159 INDIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 160 INDIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 161 INDIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 162 INDIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 163 INDIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 164 INDIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 165 INDIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 166 INDIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 167 INDIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 168 INDIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 169 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 170 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 171 SOUTH KOREA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 172 SOUTH KOREA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 173 SOUTH KOREA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 174 SOUTH KOREA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 175 SOUTH KOREA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 176 SOUTH KOREA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 177 SOUTH KOREA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 178 SOUTH KOREA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 179 SOUTH KOREA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 180 SOUTH KOREA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 181 SOUTH KOREA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 182 SOUTH KOREA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 183 SOUTH KOREA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 184 SOUTH KOREA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 185 SOUTH KOREA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 186 SOUTH KOREA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 187 SOUTH KOREA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 188 SOUTH KOREA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 189 SOUTH KOREA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 190 SOUTH KOREA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 191 SOUTH KOREA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 192 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 193 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 194 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 195 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 196 SOUTH KOREA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 197 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 198 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 199 AUSTRALIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 200 AUSTRALIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 201 AUSTRALIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 202 AUSTRALIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 203 AUSTRALIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 204 AUSTRALIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 205 AUSTRALIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 206 AUSTRALIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 207 AUSTRALIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 208 AUSTRALIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 209 AUSTRALIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 210 AUSTRALIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 211 AUSTRALIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 212 AUSTRALIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 213 AUSTRALIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 214 AUSTRALIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 215 AUSTRALIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 216 AUSTRALIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 217 AUSTRALIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 218 AUSTRALIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 219 AUSTRALIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 220 AUSTRALIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 221 AUSTRALIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 222 AUSTRALIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 223 AUSTRALIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 224 AUSTRALIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 225 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 226 SINGAPORE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 227 SINGAPORE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 228 SINGAPORE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 229 SINGAPORE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 230 SINGAPORE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 231 SINGAPORE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 232 SINGAPORE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 233 SINGAPORE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 234 SINGAPORE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 235 SINGAPORE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 236 SINGAPORE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 237 SINGAPORE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 238 SINGAPORE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 239 SINGAPORE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 240 SINGAPORE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 241 SINGAPORE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 242 SINGAPORE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 243 SINGAPORE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 244 SINGAPORE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 245 SINGAPORE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 246 SINGAPORE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 247 SINGAPORE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 248 SINGAPORE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 249 SINGAPORE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 250 SINGAPORE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 251 SINGAPORE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 252 SINGAPORE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 253 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 254 INDONESIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 255 INDONESIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 256 INDONESIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 257 INDONESIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 258 INDONESIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 259 INDONESIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 260 INDONESIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 261 INDONESIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 262 INDONESIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 263 INDONESIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 264 INDONESIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 265 INDONESIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 266 INDONESIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 267 INDONESIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 268 INDONESIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 269 INDONESIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 270 INDONESIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 271 INDONESIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 272 INDONESIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 273 INDONESIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 274 INDONESIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 275 INDONESIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 276 INDONESIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 277 INDONESIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 278 INDONESIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 279 INDONESIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 280 INDONESIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 281 THAILAND MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 282 THAILAND MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 283 THAILAND ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 284 THAILAND NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 285 THAILAND TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 286 THAILAND OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 287 THAILAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 288 THAILAND ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 289 THAILAND ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 290 THAILAND ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 291 THAILAND OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 292 THAILAND PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 293 THAILAND ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 294 THAILAND CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 295 THAILAND SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 296 THAILAND ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 297 THAILAND NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 298 THAILAND BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 299 THAILAND BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 300 THAILAND CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 301 THAILAND ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 302 THAILAND NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 303 THAILAND DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 304 THAILAND MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 305 THAILAND MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 306 THAILAND MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 307 THAILAND MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 308 THAILAND MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 309 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 310 MALAYSIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 311 MALAYSIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 312 MALAYSIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 313 MALAYSIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 314 MALAYSIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 315 MALAYSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 316 MALAYSIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 317 MALAYSIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 318 MALAYSIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 319 MALAYSIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 320 MALAYSIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 321 MALAYSIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 322 MALAYSIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 323 MALAYSIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 324 MALAYSIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 325 MALAYSIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 326 MALAYSIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 327 MALAYSIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 328 MALAYSIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 329 MALAYSIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 330 MALAYSIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 331 MALAYSIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 332 MALAYSIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 333 MALAYSIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 334 MALAYSIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 335 MALAYSIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 336 MALAYSIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 337 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 338 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 339 PHILIPPINES ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 340 PHILIPPINES NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 341 PHILIPPINES TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 342 PHILIPPINES OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 343 PHILIPPINES NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 344 PHILIPPINES ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 345 PHILIPPINES ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 346 PHILIPPINES ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 347 PHILIPPINES OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 348 PHILIPPINES PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 349 PHILIPPINES ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 350 PHILIPPINES CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 351 PHILIPPINES SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 352 PHILIPPINES ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 353 PHILIPPINES NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 354 PHILIPPINES BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 355 PHILIPPINES BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 356 PHILIPPINES CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 357 PHILIPPINES ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 358 PHILIPPINES NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 359 PHILIPPINES DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 360 PHILIPPINES MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 361 PHILIPPINES MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 362 PHILIPPINES MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 363 PHILIPPINES MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 364 PHILIPPINES MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 365 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 366 VIETNAM MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 367 VIETNAM ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 368 VIETNAM NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 369 VIETNAM TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 370 VIETNAM OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 371 VIETNAM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 372 VIETNAM ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 373 VIETNAM ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 374 VIETNAM ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 375 VIETNAM OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 376 VIETNAM PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 377 VIETNAM ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 378 VIETNAM CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 379 VIETNAM SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 380 VIETNAM ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 381 VIETNAM NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 382 VIETNAM BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 383 VIETNAM BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 384 VIETNAM CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 385 VIETNAM ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 386 VIETNAM NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 387 VIETNAM DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 388 VIETNAM MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 389 VIETNAM MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)
TABLE 390 VIETNAM MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 391 VIETNAM MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 392 VIETNAM MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 393 REST OF ASIA PACIFIC MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)
TABLE 394 SUBSIDIARIES OF JANSSEN ASIA PACIFIC SERVICES, LLC
图片列表
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC MIGRAINETREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC MIGRAINE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC MIGRAINE TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC MIGRAINE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC MIGRAINE TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC MIGRIANE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC MIGRIANE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC MIGRIANE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC MIGRAINE TREATMENT MARKET
FIGURE 11 RESULT OF PREVALENCE OF MIGRAINE FROM ONE YEAR STUDY
FIGURE 12 ASIA PACIFIC MIGRAINE TREATMENT MARKET: SEGMENTATION
FIGURE 13 INCREASING PREVALNCE OF MIGRAINE AND DEVELOPMENT OF NOVEL DRUGS IS DRIVING THE ASIA PACIFIC MIGRIANE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 14 EPISODIC IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MIGRAINE TREATMENT MARKET IN 2020 & 2027
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET IN ASIA PACIFIC MIGRAINE TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 16 ASIA PACIFIC PREVALENCE OF MIGRAINE TREATMENT (2018)
FIGURE 17 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019
FIGURE 18 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, 2019-2027 (USD MILLION)
FIGURE 19 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, CAGR (2020-2027)
FIGURE 20 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE, LIFELINE CURVE
FIGURE 21 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019
FIGURE 22 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)
FIGURE 23 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)
FIGURE 24 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 25 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 26 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)
FIGURE 27 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 28 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019
FIGURE 30 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, 2019-2027 (USD MILLION)
FIGURE 31 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, CAGR (2020-2027)
FIGURE 32 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 33 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, 2019
FIGURE 34 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 35 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 36 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 37 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, 2019
FIGURE 38 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, 2019-2027 (USD MILLION)
FIGURE 39 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 40 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 42 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 43 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 44 ASIA PACIFIC MIGRAINE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 46 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 47 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 48 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 49 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: BY TYPES OF MIGRAINE (2020-2027)
FIGURE 50 ASIA-PACIFIC MIGRAINE TREATMENT MARKET: COMPANY SHARE 2019 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
